MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has announced a strategic platform license agreement with Legend Biotech, enabling the use of MaxCyte’s cell engineering technologies for the advancement of Legend’s cell therapy programs. This partnership, which leverages MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, aims to support the development and commercialization of innovative cell-based therapeutics and could generate licensing fees, milestones, and sales royalties for MaxCyte.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
